Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 21.59%11.54B | 20.94%42.22B | 21.81%11.73B | 14.09%10.6B | 27.23%10.39B | 21.43%9.49B | 17.33%34.91B | 19.15%9.63B | 19.67%9.29B | 13.86%8.17B |
Cost of revenue | 18.87%7.13B | 21.40%26.26B | 20.54%7.22B | 13.86%6.53B | 28.59%6.51B | 23.90%6B | 18.51%21.63B | 20.21%5.99B | 21.71%5.74B | 14.21%5.07B |
Gross profit | 26.23%4.41B | 20.18%15.95B | 23.91%4.51B | 14.50%4.07B | 24.97%3.88B | 17.42%3.5B | 15.45%13.27B | 17.44%3.64B | 16.53%3.55B | 13.30%3.1B |
Operating expense | 13.75%2.49B | 10.51%9.13B | 15.52%2.46B | 8.30%2.3B | 9.38%2.18B | 8.66%2.19B | 11.89%8.26B | 10.31%2.13B | 9.93%2.12B | 12.27%1.99B |
Operating profit | 47.09%1.92B | 36.13%6.82B | 35.76%2.05B | 23.73%1.77B | 52.98%1.7B | 35.71%1.31B | 21.82%5.01B | 29.23%1.51B | 27.95%1.43B | 15.19%1.11B |
Net non-operating interest income (expenses) | -18.04%-6M | -4.98%-22.08M | -47.19%-5.44M | 20.26%-5.64M | -1.47%-5.92M | -14.61%-5.08M | -38.15%-21.03M | 29.83%-3.7M | -149.96%-7.07M | -82.45%-5.83M |
Non-operating interest expense | 18.04%6M | 4.98%22.08M | 47.19%5.44M | -20.26%5.64M | 1.47%5.92M | 14.61%5.08M | 38.15%21.03M | -29.83%3.7M | 149.96%7.07M | 82.45%5.83M |
Net investment income | -6M | -23.70%-13.32M | -20.41%-10.77M | |||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -6.05%13M | -99.93%52K | -6.06%-6.71M | -471.84%-17.24M | 8,737.39%10.16M | -82.84%13.84M | -40.07%71.42M | -176.66%-6.32M | -190.79%-3.02M | -99.12%115K |
Less:Restructuring and mergern&acquisition | ---- | ---2.73M | --0 | ---729K | ---- | ---- | --0 | --0 | --0 | ---- |
Less:Impairment of capital assets | ---- | 11.61%14.65M | -7.62%3.64M | ---- | ---- | 183.22%3.71M | --13.12M | --3.94M | --3.94M | --3.94M |
Less:Other special charges | 25.93%-13M | 86.85%-11.97M | 175.65%3.07M | 854.99%6.96M | -9.80%-4.45M | 78.59%-17.55M | 23.65%-90.99M | 50.81%-4.06M | 72.24%-922K | 69.05%-4.05M |
Less:Write off | ---- | --0 | ---- | ---- | ---- | ---- | --6.45M | ---- | ---- | ---- |
Other non-operating income (expenses) | 38.42%16M | 0.83%57.7M | 180.88%26.22M | 20.96%10.48M | 178.17%9.44M | -67.74%11.56M | 150.27%57.23M | -34.49%9.34M | 803.55%8.67M | 41.36%3.39M |
Income before tax | 45.97%1.94B | 33.99%6.84B | 36.85%2.05B | 23.19%1.76B | 54.27%1.71B | 23.47%1.33B | 20.72%5.11B | 27.34%1.5B | 27.66%1.43B | 13.21%1.11B |
Income tax | 39.31%666M | 19.78%2.3B | -7.13%593.29M | 22.27%622.95M | 52.58%600.93M | 27.84%478.07M | 32.48%1.92B | 87.75%638.87M | 21.60%509.49M | 11.64%393.84M |
Net income | 49.72%1.27B | 42.52%4.55B | 69.58%1.46B | 23.82%1.14B | 55.06%1.11B | 21.14%850.26M | 14.61%3.19B | 2.74%858.51M | 31.28%917.82M | 14.10%713.13M |
Net income continuous operations | 49.72%1.27B | 42.52%4.55B | 69.58%1.46B | 23.71%1.14B | 55.20%1.11B | 21.14%850.26M | 14.61%3.19B | 2.74%858.51M | 31.29%917.82M | 14.10%713.13M |
Noncontrolling interests | 34.20%17M | -14.62%32.48M | -171.27%-8.08M | 13.42%14.57M | 94.20%13.33M | 81.07%12.67M | -34.35%38.05M | 33.01%11.34M | 8.40%12.84M | -61.87%6.87M |
Net income attributable to the company | 49.95%1.26B | 43.21%4.52B | 72.80%1.46B | 23.97%1.12B | 54.67%1.09B | 20.54%837.59M | 15.65%3.15B | 2.43%847.16M | 31.68%904.97M | 16.35%706.27M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 49.95%1.26B | 43.21%4.52B | 72.80%1.46B | 23.97%1.12B | 54.67%1.09B | 20.54%837.59M | 15.65%3.15B | 2.43%847.16M | 31.68%904.97M | 16.35%706.27M |
Gross dividend payment | ||||||||||
Basic earnings per share | 50.11%14.11 | 42.97%50.71 | 72.87%16.44 | 23.80%12.59 | 54.27%12.28 | 20.05%9.4 | 15.42%35.47 | 2.04%9.51 | 31.23%10.17 | 16.37%7.96 |
Diluted earnings per share | 50.59%14.11 | 43.19%50.53 | 72.78%16.38 | 23.89%12.55 | 54.81%12.23 | 20.44%9.37 | 15.67%35.29 | 2.49%9.48 | 31.73%10.13 | 16.18%7.9 |
Dividend per share | 0 | 47.06%25 | 47.06%25 | 0 | 0 | 0 | 21.43%17 | 21.43%17 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |